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Abstract
Background: A few studies have assessed the short-term effects of low-dose nicotine e-cigarettes, while data about
nicotine-free e-cigarettes (NF e-cigarettes) are scanty. Concerns have been expressed about the use of NF e-cigarettes,
because of the high concentrations of propylene glycol and other compounds in the e-cigarette vapor.
Methods: This laboratory-based study was aimed to compare the effects of ad libitum use of a NF e-cigarette or and a
traditional cigarette for 5 min in healthy adult smokers (n = 10) and non-smokers (n = 10).
The main outcome measures were pulmonary function tests, fraction of exhaled nitric oxide (FeNO) and fractional
concentration of carbon monoxide (FeCO) in exhaled breath.
Results: The traditional cigarette induced statistically significant increases in FeCO in both smokers and non-smokers,
while no significant changes were observed in FeNO. In non-smokers, the traditional cigarette induced a significant
decrease from baseline in FEF75 (81 % ± 35 % vs 70.2 % ± 28.2 %, P = 0.013), while in smokers significant decreases were
observed in FEF25 (101.3 % ± 16.4 % vs 93.5 % ± 31.7 %, P = 0.037), FEV1 (102.2 % ± 9.5 % vs 98.3 % ± 10 %, P = 0.037) and
PEF (109.5 % ± 14.6 % vs 99.2 % ± 17.5 %, P = 0.009). In contrast, the only statistically significant effects induced by the NF
e-cigarette in smokers were reductions in FEV1 (102.2 % ± 9.5 % vs 99.5 ± 7.6 %, P = 0.041) and FEF25 (103.4 % ± 16.4 %
vs 94.2 % ± 16.2 %, P = 0.014).
Discussion: The present study demonstrated that the specific brand of NF e-cigarette utilized did not induce
any majoracute effects. In contrast, several studies have shown that both traditional cigarettes and nicotine-
containing e-cigarettes have acute effects on lung function. Our study expands on previous observations on
the effects of NF e-cigarettes, but also for the first time describes the changes induced by smoking one
traditional cigarette in a group of never smokers.
Conclusions: The short-term use of the specific brand of NF e-cigarette assessed in this study had no immediate
adverse effects on non-smokers and only small effects on FEV1 and FEF25 in smokers. The long-term health effects
of NF e-cigarette use are unknown but worthy of further investigations.
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Background
Electronic cigarettes (e-cigarettes) have been proposed
as a novel method for quitting smoking. The producers
of e-cigarettes claim that one of the benefits of these cig-
arettes is that a smoker may gradually decrease the nico-
tine content over time, until a state of “nicotine-free”
smoking is reached. This state can be reached without
the smoker having to renounce “habit-automatisms” and
handling, which are major obstacles to quitting smoking.
However, the recent position statement of the Forum
of International Respiratory Societies [1] on the use of
e-cigarettes and their potential hazards concluded that
these devices should be restricted or banned until more
information about their safety is available. The major
concerns include the nicotine content and the potential
harm due to the high concentrations of propylene gly-
col, which is irritant when inhaled, chemicals, such as
quinoline, benzoic acid and diethylcarbonate, and other
compounds found in the e-cigarette vapor.
To our knowledge there are no data on the health effects
of acute use of nicotine-free e-cigarettes (NF e-cigarettes);
we, therefore, designed a study to compare the changes in
pulmonary function tests (PFT) and fractions of exhaled
nitric oxide (FeNO) and carbon monoxide (FeCO) as a re-
sult of 5 min of ad libitum smoking of a NF e-cigarette or
a traditional cigarette, in smokers and non-smokers.
Methods
Subjects
Twenty normal subjects, recruited among pulmonary fel-
lows or attending physicians were studied: 10 were
smokers (minimum of 5 pack-years) and 10 were non-
smokers. Exclusion criteria were current use of any medi-
cation, the presence of any acute or chronic lung disease,
neuromuscular diseases, cancer, chronic heart failure,
metabolic or auto-immune diseases and acute illness dur-
ing the preceding 4 weeks. Each subject was asked to sign
written informed consent to the protocol approved by the
Salvatore Maugeri Ethical Committee. The protocol was
registered at www.clinicaltrials.gov with the number
NCT02102191 on March 27, 2014.
Protocol
Both smokers and non-smokers were randomized to
smoke both the NF e-cigarette and a commercial “popular
brand” standard cigarette ad libitum for 5 min in two dif-
ferent sessions according to a cross-over design (5 patients
within each group smoked first the NF e-cigarette and
then the commercial cigarette and 5 subjects smoked first
the commercial and then the NF e-cigarette). All subjects
were asked to use a similar pattern and frequency of
smoke aspiration, although it cannot be assured that they
did so. The subjects were also asked to refrain from
smoking in the 6 h preceding the test session and not to
eat or drink for at least 4 h prior to the experimental
procedure.
The first smoking session started 5 min after the base-
line measurement of FeCO, FeNO and PFT. The second
smoking session started after a wash-out of 24 h after
the end of the first session. This wash-out period was to
ensure that there was no carry-over effect. The measure-
ments of FeNO, FeCO and PFTs were repeated immedi-
ately after each smoking session.
The NF e-cigarette used in this study, ELIPS C Series
(Ovale Europe S.r.l., Desenzano del Garda, Brescia, Italy),
was a brand commercially available in Italy. It was formed
of a steel shell with a microprocessor powered by a bat-
tery, a filter and a removable cartridge. Among the six dif-
ferent types of cartridge available, we chose “Natur Smoke
aroma Nocciola Antistress 0 mg/mL nicotina” (Angelica,
Bologna, Italy), i.e., a nicotine-free liquid with a hazelnut
flavorThe liquid of the cartridge is registered by the Italian
Regulatory Agency and had the following composition:
glycerin >50 %, isotonic solution 5–10 %, magnesium
chloride 1–5 %, natural flavor 0.1–1 %, and vitamin B12
0.1–1 %. The specific kind of NF e-cigarette chosen in the
current study followed an unbiased internet search for
products available and produced in Italy (e.g.Dea, Flatech,
Flavour Roma). Use of the Angelica liquid was finally de-
cided mainly due to logistic convenience since it was pro-
duced in the same city (Bologna) of investigation.
The commercial standard cigarette, Marlboro® Red Label
Box (Philip Morris USA Inc., Miami, FL, USA), contained
nicotine 0.8 mg, carbon oxide (CO) 10 mg and tar 10 mg.
According to the manufacturer [2], the components not
exceeding 0.1 % of the weight of the tobacco were acetic
acid 0.01, acetophenone 0.0001, ammonium hydroxide
0.3, amyl butyrate 0.0001, benzaldehyde 0.005, benzoin
0.005, benzyl alcohol 0.1, cellulose 9.3, calcium carbonate
4.6, monopotassium phosphate 1.4, potassium citrate 0.3,
guar gum 0.1, and hercon70 0.1.
Measurements
The exhaled nitric oxide (FeNO) and fractional concen-
tration of carbon monoxide in exhaled breath (FeCO)
were measured using chemiluminescense analyzers
(NIOX MINO, Aerocrine AB, Solna, Sweden and Micro
Smokerlyzer, Bedfont Scientific Ltd., Rochester, Kent,
Great Britain, respectively) with a computerized pro-
gram. The FeNO analyzer was calibrated with certified
NO mixtures (100 ppb) in nitrogen.
PFT were performed with a spirometer (Chestgraph
HI-105 - CHEST M.I. Inc, Tokyo, Japan). The following
parameters were recorded in the sitting position: forced
vital capacity (FVC), forced expiratory volume in 1 s
(FEV1), forced expiratory flow (FEF) 25 %, 50 % and
75 % and peak expiratory flow (PEF). Spirometry was
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performed following the recommendations of the
American Thoracic Society/European Respiratory Soci-
ety (ATS/ERS) guidelines [3].
For the FeNO recording, the subjects were studied in
the sitting position wearing a nose-clip and were asked
to inhale as deeply as they could, to total lung capacity,
while breathing through a mouthpiece and then to ex-
hale at a flow rate of about 50 mL/s, maintaining a con-
stant mouth pressure of 4 to 5 cm H2O for 10 s, aided
by visual feedback on the screen of the instrument.
Each of the three different measurements (FeNO, FeCO
and PFT) were separated by intervals of about 45 s.
Statistical analysis
Data are expressed as mean ± SD or as frequencies. A
Kolmogorov-Smirnov non-parametric test was applied to
test the normality of the distributions. Two-way ANOVA
was applied to the differences observed between basal
values and those after smoking a traditional cigarette or
an e-cigarette, considering smoking habit and the cross-
over design as factors. The effects estimated by ANOVA
are reported together with their 95 % confidence intervals
(95 % CI). A two-tailed P value less than 0.05 is considered
statistically significant. All analyses were performed using
SPSS for Windows (ver. 21, IBM Corporation, Armonk,
NY, USA).
Sample size
Prokhorov et al. found a decrease of 2.14 % in the pre-
dicted value of FEV1 in 18 volunteer, regular smokers after
smoking one traditional cigarette [4]. Since the standard
deviation of the within-subject difference was not re-
ported, we have estimated this value as 3.26 % (one third
of the value reported as the overall standard deviation in
the study by Prokhorov et al.; i.e., 9.78 %) [4]. By compar-
ing these values versus no effect of the e-cigarette, we had
to study 20 subjects in order to be able to reject the null
hypothesis with a probability (power) of 0.80 and a
two-sided type I error probability of 0.05. We, there-
fore, set the sample size as 20 subjects (10 smokers and
10 non-smokers), hypothesizing similar effects of
smoking one traditional cigarette between smokers and
non-smokers. The sample size was estimated by means
of “PS Power and Sample Size Calculations” software
(Version 3.0.43; Department of Statistics of the Vander-
bilt University, Nashville, TN, USA; http://biostat.mc.-
vanderbilt.edu/twiki/bin/view/Main/PowerSampleSize)
according to Dupont and Plummer [5].
Results
The subjects’ characteristics are reported in Table 1.
All the subjects completed the study protocol. A few
non-smokers reported mild adverse events such as dry
cough (n = 3) and throat irritation (n = 2) when smoking
traditional cigarettes.
FeCO and FeNO
The FeCO values in the smokers and non-smokers are
shown in Figure 1. As expected, baseline FeCO values
were significantly higher in smokers than in non-
smokers (P < 0.001,two-way ANOVA). The signify
cance values, using the two-way ANOVA analysis, of the
changes of FeCO values versus the baseline ones observed
in smokers and non-smokers after smoking each type of
cigarette, as well as the comparison between the traditional
and e-cigarette, are also shown in Fig. 1 while the estimated
effects of the two different types of cigarette in the overall
population and the comparison of these effects between
smokers and non-smokers, using the two-way ANOVA
analysis, are presented in Table 2. In the 20 subjects studied
the traditional cigarette significantly increased FeCO
values (P < 0.001); this effect was significant in both
groups of subjects (smokers P < 0.001; non-smokers
P = 0.043). In contrast, the e-cigarette did not have
any significant effects on FeCO (overall population
P = 0.486; smokers P = 0.226; non-smokers P = 0.804).
The increase of FeCO values observed after smoking
the traditional cigarette was significantly different
from the effect of the e-cigarette (overall population
P < 0.001; smokers P < 0.001; non-smokers P = 0.048).
As far as the comparison between smokers and non-
smokers is concerned, no significant differences were
found (traditional cigarette P = 0.127; e-cigarette P = 0.301).
Likewise, the difference observed between the two types of
Table 1 Subjects’ characteristics
Overall Smokers Non-smokers P value
Gender (M/F) 11/9 4/6 7/3 0.370a
Age (mean ± SD, years) 39.3 ± 12.6 42.3 ± 12.8 36.2 ± 12.3 0.291b
Weight (mean ± SD, kg) 67.9 ± 10.4 63.5 ± 10.1 72.3 ± 9.2 0.056b
Height (mean ± SD, cm) 169. ± 10.0 163 ± 7.4 176 ± 8.3 0.002b
BMI (mean ± SD, kg/m2) 23.5 ± 2.5 23.7 ± 3.1 23.3 ± 1.9 0.704b
Smoke history (pack-years) - mean ± SD (range) - 19.4 ± 10.8 (5–35) - -
aFisher’s exact test
bt-test for equality of means
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cigarette was not significant between smokers and non-
smokers (P = 0.067).
Baseline values of FeNO were not significantly different
between smokers and non-smokers (P = 0.245, two-way
ANOVA). No significant changes of FeNO were observed
in the two groups of subjects after smoking either a trad-
itional or e-cigarette (Fig. 2, two-way ANOVA) and no sig-
nificant changes were found in the overall group of
subjects studied (Table 2).
Pulmonary function tests
All baseline pulmonary function tests (FEV1, FVC,
FEV1/FVC, and PEF) were similar between smokers and
non-smokers (P ≥ 0.157,Two-way ANOVA).
Smoking a traditional cigarette significantly de-
creased the FEV1/FVC in non-smokers (P = 0.047 two
way ANOVA; Fig. 3). In addition, both types of ciga-
rettes significantly decreased FEV1 values in smokers
(traditional P = 0.037; electronic P = 0.041, two-way
ANOVA) while the decreases in non-smokers were not
significant; thus FEV1 decreased significantly in the
overall population (P = 0.013, Two-way ANOVA) after
smoking a traditional cigarette while the effect of the
e-cigarette did not reach a statistically significant level
(P = 0.070, Two-way ANOVA). Finally, the traditional
cigarette significantly decreased PEF values in the over-
all population (P = 0.017, Two-way ANOVA) due to ef-
fect in the smokers (P = 0.009,Two-way ANOVA). The
changes in FEV1, FVC, FEV1/FVC, and PEF between
the two types of cigarettes were not significantly differ-
ent in either smokers or non-smokers (Fig. 3) or, in-
deed in the overall population (Table 2).
As far as FEF values are concerned, the traditional
cigarette significantly decreased FEF25, FEF50 and FEF75
in the overall population (P = 0.030, P = 0.033, and P =
0.040, respectively, two-way ANOVA; Table 2), particu-
larly due to the significant reductions of FEF25 in smokers
(P = 0.037) and FEF75 in non-smokers (P = 0.013) while
the reduction of FEF50 did not reach the significant levels
in either smokers (P = 0.213) or non-smokers (P = 0.063)
(Fig. 4). The only significant effect of the e-cigarette was a
reduction of FEF25 in smokers (P = 0.014, two-way
ANOVA). Comparing the effects of traditional and e-
cigarette smoking, only a significantly greater reduction of
FEF50 was found after traditional cigarette smoking in
non-smokers (P = 0.036, two-way ANOVA).
As far as concerns the comparison between smokers
and non-smokers, higher values of FEF75 were found
after smoking an e-cigarette than after smoking a trad-
itional cigarette, whereas the inverse was the case in
smokers (P = 0.037, two-way ANOVA) (Table 2,
Fig. 4c).
Discussion
We found that the specific brand of NF e-cigarettes used
in this study was not associated with major acute physio-
logical changes, causing only small, albeit statistically
significant decreases in FEF25 and FEV1 in the group of
smokers. In contrast, smoking a traditional cigarette in-
duced immediate bronchoconstriction in non-smokers.
Tobacco cigarettes are one of the most important risk
factors for disease worldwide and the primary goal of to-
bacco control is to reduce the mortality and morbidity
associated with its use.
E-cigarettes have gained popularity in the last few
years, mainly because of the advertisements of their pro-
ducers, who claim that smoking tar-free cigarettes is as-
sociated with reduced risk for the health.
A recent systematic review assessing the efficacy of e-
cigarettes included six experimental studies and six cohort
studies. The authors concluded that the use of e-cigarettes
Fig. 1 Changes in fractional concentration of carbon monoxide in exhaled breath (FeCO) in smokers and non smokers
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can reduce the number of cigarettes smoked and with-
drawal symptoms, but that it was associated with some ad-
verse events, such as mouth and throat irritation, nausea,
headache and dry cough [6].
E-cigarettes have been shown to induce immediate ad-
verse physiological effects after short-term use, similar to
those observed with tobacco smoking [7]. The statement
of the Forum of International Respiratory Societies [1] on
the use of e-cigarettes and their potential hazards con-
cluded that, considering the above-mentioned facts, the
use of these devices should be restricted until more infor-
mation on their safety becomes available.
More recently, NF e-cigarettes have been released
on the market with the aim of minimizing the
Table 2 Effects of the two different types of cigarette
Overall population Smokers vs. non smokers
Effect 95 % CI P Effect 95 % CI P
FeCO (ppm)
Traditional 4.3 (2.3 to 6.2) <0.001 2.9 (−0.9 to 6.7) 0.127
Electronic −0.2 (−0.8 to 0.4) 0.486 −0.6 (−1.8 to 0.6) 0.301
P value <0.001 0.067
FeNO (ppb)
Traditional −0.6 (−1.6 to 0.4) 0.219 1.4 (−0.6 to 3.4) 0.155
Electronic −0.2 (−0.8 to 0.4) 0.512 0.8 (−0.5 to 2.1) 0.198
P value 0.372 0.501
FEV1 (%)
Traditional −3.4 (−5.9 to −0.8) 0.013 −1.0 (−6.1 to 4.1) 0.691
Electronic −1.7 (−4.8 to 2.9) 0.070 −2.1 (−5.7 to 1.6) 0.250
P value 0.098 0.575
FVC (%)
Traditional −1.6 (−5.7 to 2.6) 0.437 −3.9 (−12.2 to 4.4) 0.331
Electronic −1.0 (−4.8 to 2.9) 0.602 −2.2 (−9.8 to 5.4) 0.543
P value 0.584 0.448
FEV1/FVC
Traditional −1.9 (−3.9 to 0.1) 0.065 2.0 (−2.0 to 6.1) 0.304
Electronic −0.9 (−2.5 to 0.6) 0.226 −0.1 (−9.8 to 3.0) 0.926
P value 0.182 0.132
PEF (%)
Traditional −6.5 (−11.7 to −1.3) 0.017 −7.5 (−17.8 to 2.9) 0.148
Electronic −3.8 (−9.2 to 1.6) 0.155 −6.0 (−16.8 to 4.8) 0.254
P value 0.145 0.692
FEF25 (%)
Traditional −5.8 (−10.9 to −0.6) 0.030 .4.1 (−14.1 to 6.2) 0.412
Electronic −3.7 (−7.6 to 0.3) 0.066 −7.1 (−15.0 to 0.7) 0.073
P value 0.252 0.414
FEF50 (%)
Traditional −5.0 (−9.5 to −0.4) 0.033 2.1 (−6.9 to 11.1) 0.629
Electronic −2.9 (−6.8 to 1.1) 0.143 −2.9 (−10.8 to 5.0) 0.447
P value 0.161 0.096
FEF75 (%)
Traditional −6.1 (−11.9 to −0.3) 0.040 9.3 (−2.3 to 20.9) 0.107
Electronic −4.8 (−11.2 to 1.6) 0.132 3.6 (−16.4 to 9.3) 0.562
P value 0.657 0.037
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adverse events linked with the use of nicotine-
delivering e-cigarettes.
One of the concerns of using NF e-cigarettes is that
the devices contain high concentrations of glycol, which
is a known irritant when inhaled. Other potentially dan-
gerous ingredients that may be found in NF e-cigarettes
are solvents, genotoxins and various other chemicals and
animal carcinogens (e.g., benzoic acid, quinoline).
The act of ‘smoking’ an e-cigarette is called ‘vaping’
and it mimics smoking so, in addition to delivering
nicotine, it can address both pharmacological and be-
havioral components of cigarette addiction. Indeed, the
Fig. 2 Changes in fraction of exhaled nitric oxide (FeNO) in smokers and non smokers
Fig. 3 Changes in pulmonary function tests in smokers and non smokers
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notable reduction in craving achieved by NF e-cigarettes
demonstrates the ability of physical stimuli to suppress
cravings independently of the administration of nicotine
[8–13].
In a randomized, controlled trial of smoking cessation
aided by nicotine e-cigarettes, NF e-cigarettes or nico-
tine patches performed in 657 people, Bullen et al. [13]
found a rather disappointing percentage of abstinence at
6 months and the modest overall effect of the three
methods (nicotine e-cigarettes, NF e-cigarettes, nicotine
patches) did not allow a demonstration of the superiority
of nicotine e-cigarettes over NF e-cigarettes.
The present study demonstrated that the specific
brand of NF e-cigarette utilized did not induce any
major acute effects. In contrast, several studies have
shown that both traditional cigarettes and nicotine-
containing e-cigarettes have acute effects on lung
function: Vardavas et al. [7] showed that e-cigarettes
containing a dose of 11 mg of nicotine significantly
increased the impedance and resistance after 5 min of
smoking, while Flouris et al. [12] demonstrated a signifi-
cant immediate decrease in lung function only when
smoking traditional cigarettes and not with e-cigarettes.
Similar data were also reported by Unverdorben et al.
[14], who showed a significantly greater decrease in
specific airway conductance and FEF25 after smoking a
conventional cigarette than after a low nicotine (5 mg)
e-cigarette.
Our study expands on previous observations on the
effects of NF e-cigarettes, but also for the first time de-
scribes the changes induced by smoking one traditional
cigarette in a group of never smokers. Interestingly in
these subjects the decreases in PFT values were much
more pronounced (although not-significantly) than in
the smokers, possibly because the airways of the former
were more ‘naïve’ to noxious stimuli, which may have
induced greater narrowing of the lumen of the periph-
eral airways, due to localized edema or smooth muscle
contraction. The change in pulmonary function of the
smokers was less pronounced than that reported in
some previous studies and did not achieve statistical sig-
nificance, despite the rate of change being quite similar
to the above mentioned investigations. This may be due
to the less sophisticated method of assessing airway nar-
rowing in our study than in the study by Vardavas et al.
(PTF vs impulse oscillometry, respectively) [7] or the
Fig. 4 Changes in ”small airways flows” in smokers and non smokers
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longer and more intense habit of smoking of our group
of subjects, which could have minimized the response.
The specific brand of NF e-cigarettes used in the present
study did not induce any significant changes in smokers
apart from decreases in FEV1 and FEF25. This latter find-
ing is not easy to explain, and there are no investigations
so far that have assessed the potential role of components
of NF e-cigarettes on airway reactivity. Although both
groups of subjects inhaled effectively - as illustrated by the
significant increase in FeCO - only the group of active
smokers reached levels of CO suggestive of deep inhal-
ation (about 20 ppm), while the non-smokers had lower
values (about 5 ppm). The higher levels of FeCO observed
in smokers than in non-smokers may be explained by the
previous CO exposure from tobacco smoking in the
former. Indeed, according to the study protocol, smokers
should have refrained from smoking in the 6 h preceding
the experiments while the half-life of expired CO is about
4 h, depending on exercise.
As expected, the FeNO level was reduced in the
smokers, but no significant changes were observed in
either group after cigarettes smoking. This is in contrast
to what was observed in several studies [15–18], but not
with the data of Chambers et al. [19] who found an in-
crease in the level of exhaled NO minutes after smoking a
traditional cigarette. Balint et al. [20] also found no signifi-
cant change in the concentration of exhaled NO after
smoking two cigarettes, but the concentrations of NO me-
tabolites (NO2
− +NO3
−) were significantly increased. These
findings suggest that NO might be trapped at the epithe-
lial surface of airways in the formation of bioequivalent
oxides of nitrogen such as peroxynitrite and S-nitrosothio.
The present study has some limitations that need to
be discussed. First, the technique used to detect airway
narrowing may not be as sensitive as the impulse oscil-
latory technique and it has been shown that changes in
flow resistance usually precede variations in PFT. In-
deed we assessed only crude spirometry, while DLCO
and lung volumes and perhaps measurements of airway
reactivity and particulate/vapor burden, may have given
more insights into the problem. The ad libitum smok-
ing of the cigarette may also be criticized because of
the lack of standardization between subjects and be-
cause it is likely that a current smoker would smoke
more than a non–smoker. The sample size (20 subjects)
may be considered quite small, although it was based on a
sophisticated calculation involving previously reported
data (4,5), so we are confident that the data collected
may be representative enough of the changes induced
by smoking either NF e-cigarettes or traditional ones.
Conclusions
In conclusion, smoking the NF e-cigarette studied in the
present investigation had no immediate adverse effects
after short-term use in non-smokers and a small effect
on FEV1 and FEF25 in smokers. In contrast, acute trad-
itional cigarette smoking was associated with more detri-
mental effects on PFT in non-smokers than in smokers,
although differences were not statistically significant.
The long-term health effects of NF e-cigarette use are
unknown but worthy of further investigation.
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